Isoform-selective decrease of glycogen synthase kinase-3 beta (GSK-3β) reduces synaptic tau phosphorylation, trans-cellular spreading and aggregation, iScience, January 2021.
Co-author, “Distinct cytokine profiles in human brains resilient to Alzheimer’s pathology,” Neurobiology of Disease, January 2019.
Co-author, “[F-18]-AV-1451 binding profile in chronic traumatic encephalopathy: a postmortem case series,” 12th Human Amyloid Imaging Conference, Miami, FL, January 2018.
Co-author, “Lessons learned about [F-18]-AV-1451 off-target binding from an autopsy-confirmed Parkinson’s case,” Acta Neuropathoogica Communications, October 2017.
Co-author, “[F-18]-AV-1451 binding correlates with postmortem neurofibrillary tangle Braak staging,” Acta Neuropathologica, October 2017.
Co-author, “Pathologic correlations of [F-18]-AV-1451 imaging in non-Alzheimer tauopathies,” Annals of Neurology, January 2017.
Co-author, “In vivo [F-18]-AV-1451 (T807) PET imaging in the first two autopsy-confirmed non-Alzheimer tauopathy cases,” 10th Human Amyloid Imaging Conference, Miami, FL, January 2016.
Co-author, “Activation of glycogen synthase kinase-3 beta mediates β-amyloid induced neuritic damage in Alzheimer’s disease,” Neurobiology of Disease, January 2012.